SA
SNPHY logo
Santen Pharmaceutical Co., Ltd.(SNPHY)
Closing price · checked 6:13 PM ETAbout this dataData status
$12.50▼-0.06 (-0.48%)
Extended:$12.65+0.15 (+1.20%)· 6:13 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Santen Pharmaceutical Co., Ltd. (SNPHY)

R&D to Revenue

8.98%

Fiscal year · Period ending:

SNPHY logo

SNPHY R&D to Revenue

Latest reported8.98%
SNPHY FY R&D/Revenue (13.61% → 8.98%)
High-resolution chart · PNG

What is r&d to revenue?

R&D spending as percentage of revenue.

SNPHY r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it, in percentage points.

Santen Pharmaceutical Co., Ltd. R&D to Revenue — Annual fiscal periods
Period endingR&D to RevenueChange
8.979%+1.16 pts
7.8222%−0.36 pts
8.1807%−1.96 pts
10.1409%+0.23 pts
9.9066%+0.25 pts
9.6601%+0.27 pts
9.3892%−0.49 pts
9.8827%−0.63 pts
10.512%−0.58 pts
11.0886%+0.85 pts
10.236%−0.56 pts
10.7995%−0.73 pts
11.5288%−2.51 pts
14.0418%−1.01 pts
15.0547%+3.12 pts
11.931%−0.84 pts
12.7701%−5.39 pts
18.1631%+5.65 pts
12.5162%−14.68 pts
27.1941%+13.00 pts
14.1986%+0.59 pts
13.6133%—

Frequently asked questions: SNPHY r&d to revenue

What is Santen Pharmaceutical Co., Ltd. (SNPHY)'s current r&d to revenue?

Santen Pharmaceutical Co., Ltd. (SNPHY)'s latest reported r&d to revenue (Fiscal year) is 8.98% as of Mar 31, 2026. R&D spending as percentage of revenue.

How much historical r&d to revenue data is available for SNPHY?

Stock Alarm Pro provides 22 dated annual fiscal periods observations for Santen Pharmaceutical Co., Ltd. (SNPHY)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare SNPHY's r&d to revenue to peers or set an alert?

You can open SNPHY's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on SNPHY delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.